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ABSTRACT: Inborn errors of metabolism in adults are
still largely unexplored. Despite the fact that adult-onset
phenotypes have been known for many years, little atten-
tion is given to these disorders in neurological practice.
The adult-onset presentation differs from childhood-
onset phenotypes, often leading to considerable diag-
nostic delay. The identiﬁcation of these patients at the
earliest stage of disease is important, given that early
treatment may prevent or lessen further brain damage.
Neurological and psychiatric symptoms occur more fre-
quently in adult forms. Abnormalities of eye movements
are also common and can be the presenting sign. Eye
movement disorders can be classiﬁed as central or
peripheral. Central forms are frequently observed in lyso-
somal storage disorders, whereas peripheral forms are a
key feature of mitochondrial disease. Furthermore, oculo-
gyric crisis is an important feature in disorders affecting
dopamine syntheses or transport. Ocular motor disorders
are often not reported by the patient, and abnormalities
can be easily overlooked in a general examination. In
adults with unexplained psychiatric and neurological
symptoms, a special focus on examination of eye move-
ments can serve as a relatively simple clinical tool to
detect a metabolic disorder. Eye movements can be eas-
ily quantiﬁed and analyzed with video-oculography, mak-
ing them a valuable biomarker for following the natural
course of disease or the response to therapies. Here, we
review, for the ﬁrst time, eye movement disorders that
can occur in inborn errors of metabolism, with a focus on
late-onset forms. We provide a step-by-step overview
that will help clinicians to examine and interpret eye
movement disorders. © 2018 The Authors. Movement
Disorders published by Wiley Periodicals, Inc. on behalf
of International Parkinson and Movement Disorder
Society.
Key Words: eye movement disorders; inborn errors of
metabolism; movement disorders; adult-onset
Inborn errors of metabolism (IEM) are a heteroge-
neous group of genetic disorders that cause dysfunction
of an enzyme or transporter involved in cellular metab-
olism. Historically, inborn errors were thought to be
rare, occuring in less than 1 per 100,000 live births and
to only present during infancy or early childhood.1 We
now know that this prevalence is an underestimate, and
that IEM present in adolescence or adulthood much
more often than previously thought. Retrospective data
from an ethnically diverse population in the United
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Kingdom (1999-2003) revealed an overall prevalence
of metabolic disease of 1 per 784 live births; mitochon-
drial diseases, lysosomal storage diseases, and amino
acid disorders were most frequent. Furthermore, more
than one quarter of all diagnoses were made after the
age of 15 years.2 Adult phenotypes may differ from the
classic childhood-onset phenotypes. In adulthood,
many IEM patients present with neurological or psychi-
atric symptoms, but considering an IEM in the differen-
tial diagnosis of an adult patient is still uncommon
among neurologists.3 Missing or delaying diagnosis of
an IEM can have important implications. In particular,
patients with a milder phenotype appear to beneﬁt most
from timely treatment, so identifying them is important
to prevent further (neurological) damage.4
Whereas the neurological symptoms in patients with
IEM often involve various types of movement
disorders,5 eye movement disorders are also frequently
observed and can be an important diagnostic clue.6 The
type of eye movement disorder can often further delin-
eate the type of IEM.
The aim of this article is to review the abnormalities
of eye movements that can be observed in IEM, with
an emphasis on those IEMs that can present later in
life. Our goal is to increase awareness of eye
movements in adult patients with movement disorders
and other neurological or psychiatric disturbances
because they can be the key to early diagnosis.
Because more types of IEM are being identiﬁed that
can be treated, early recognition of these disorders is
important.
Search Strategy and Selection
Criteria
We reviewed articles regarding ocular motility disor-
ders and IEM up to June 2017. References were identi-
ﬁed by PubMed, text book search, and through
citations in relevant articles and books. Only articles
published in English were included. Search terms are in
Supplementary Appendix I. Only IEMs with at least
2 patients with some type of eye movement disorder
were included in the review. Although we focused on
late-onset IEM (adolescent-onset 16-18 years of age,
adult-onset > 18 years of age), it is difﬁcult to discrimi-
nate speciﬁcally between early- and late-onset forms,
given that eye movement disorders are frequently not
described in the literature. For that reason, children were
also included in this review. We included mitochondrial
diseases as a combined disease group instead of speciﬁc
subtypes. We excluded articles in which nystagmus sec-
ondary to blindness was the only ocular motor ﬁnding.
Supplementary Appendix II presents a list of references
with videos of eye movement disorders in IEM.
Examination of Eye Movements
Disorders of eye movement can be categorized as
peripheral and central (Table 1). Peripheral eye move-
ment disorders are particularly frequent in mitochron-
drial disorders and commonly affect the two eyes
differently, resulting in ocular misalignment and diplo-
pia. Progressive external ophthalmoplegia (PEO) is an
important exception to this rule.7 Because of the insidi-
ous onset and slow progression, patients do not com-
plain of diplopia and may be unaware of any disorder
of eye movements.8 Central causes of ocular motor
abnormalities usually affect both eyes.7,9
Clinical examination of the eye movements in all
patients with a suspected IEM is essential. Patients
themselves may not report visual symptoms or may
only have nonspeciﬁc complaints.9,10 Table 2 provides
a short step-by-step overview of the clinical examina-
tion of eye movements. Every step in the table needs to
be followed because different types of eye movement
disorders can exist in 1 patient.
Video-oculography (VOG) allows for better quan-
titative documentation of abnormalities. Typically,
a digital camera mounted in goggles uses the con-
trast between the pupil and iris to track the move-
ment and position of one or both of the eyes.11
TABLE 1. Peripheral and central eye movement disorders
Anatomical Location Abnormality During Examination
Peripheral origin Retina and optic nerve Nystagmus
Ocular muscles, ocular nerves and nuclei (oculomotor, trochlear,
abducens)
Impaired range of motion, strabismus, abnormal smooth pursuit,
saccades, vestibulo-ocular reﬂex, and optokinetic nystagmus
Peripheral vestibular system Nystagmus
Central origin Central visual pathways and cortex Nystagmus
Cerebellum and brainstem Impaired range of motion, abnormal smooth pursuit, saccades,
vestibulo-ocular reﬂex, and optokinetic nystagmus
Frontoparietal cortex, basal ganglia, and cerebellum Oculomotor apraxiaa, impaired smooth pursuit
Basal ganglia and midbrain Oculogyric crisisb
aOculomotor apraxia: failure of saccade initiation.
bOculogyric crisis: episodes of tonic upward conjugate deviation of the eyes with an inability to look downward.
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VOG is an effective user- and patient-friendly tool
to quantify eye movements, including subtle changes
in latency, velocity, and accurary of saccades.12 It
can be used to support or make a diagnosis and
measure effectiveness of treatment during follow-up.
For example, in Niemann-Pick type C (NP-C), sac-
cadic parameters measured by VOG have been
reported to be a robust indicator of efﬁcacy of
treatment with Miglustat.13
Inborn Errors of Metabolism
Associated With Ocular Motor
Disorders
We will discuss abnormalities of eye movements in
IEM. An overview of the various IEMs associated with
ocular motor disorders, including the underlying gene
defect, metabolic abnormalities, age of onset, early-
TABLE 2. Seven-step examination of eye movements (modiﬁed from both Leigh and Strupp9,10)
Type of Examination Abnormalities
Step 1
Inspection Posture of head and neck Head turn or tilt in diplopia, gaze palsy, dystonia, or
otolith disorders. Head thrusts in saccade initiation
disorders (ocular motor apraxia)
Face and eyelids Blepharospasm, ptosis
Step 2
Examination of vision, pupils, and
fundus
Vision Impaired visual acuity
Confrontation visual ﬁelds Visual ﬁeld defect
Pupillary reﬂexes Delayed or absent, light to near dissociation
Fundus Pathology of the retina or optic nerve, subtle forms of
nystagmus or saccadic oscillations
Step 3
Fixation, range of motility, and
alignment
Gaze in center and eccentric position, Vergence Limited range of motion of one or both eyes Strabismus
(horizontal and vertical misalignment) Saccadic
intrusions (square-wave jerks) during ﬁxation Gaze
palsy Primary position or gaze-evoked nystagmus
Oculogyric crises
Step 4
Frenzel’s spectacles to eliminate
ﬁxation or occlusive
ophthalmoscopy (cover one eye
while viewing the fundus of the
other)
Gaze in center and eccentric position Spontaneous nystagmus brought out by removal of
ﬁxation
Step 5




-command (look left-right, up-down)
-Saccades to speciﬁc targets (pen-ﬁnger)
-Rapid self-paced saccades between two speciﬁc
targets
-Antisaccades (look at the mirror location in the
opposite direction to the target when it appears or
moves)
Impaired initiation: ocular motor apraxia Increased





Tracking a small, smoothly moving target in
horizontal and vertical directions with head still or
with head moving (vestibular suppression)
Corrective, catch-up saccades (tracking with head still)
or back-up saccades (tracking with head moving) to
reacquire the ﬁxation target
Optokinetic drum or tape in horizontal and vertical
direction
Not inducible, direction asymmetry
Step 7
Vestibulo-ocular reﬂex Head-impulse testa (passive rapid turning of the
head while ﬁxation on a stationary target)
Corrective saccades instead of stable ﬁxation
Head-shaking test (oscillate head 20 times) Post head shaking nystagmus in peripheral and in
central vestibular disorders
aThe head impulse test maximizes the ability of the vestibular system to overcome a supranuclear palsy.
1846 Movement Disorders, Vol. 33, No. 12, 2018
K O E N S E T A L .
onset symptoms, and treatment, is given in Table 3.
Table 4 presents the described eye movement disorders
for each of those IEMs.
Lysosomal Storage Diseases
Late-onset NP-C usually presents with neurological
problems. Movement disorders are frequent, particu-
larly in these adolescent- and adult-onset forms.14 Eye
movement disorders are also an important feature. Ver-
tical supranuclear gaze palsy (VSGP) is a key feature
and is present in approximately 65% of patients.15
VSGP in patients with NP-C is characterized by a paral-
ysis of vertical (especially downward) saccades, whereas
smooth pursuit is initially spared.16 Horizontal sac-
cades are initially preserved, but are ultimately affected
as the disease progresses.17,18 A so-called round-the-
houses phenomenon occurs when attempting vertical
saccades: The eyes do not move directly up and down,
but in a lateral arc (Video 1).16,19 A similar phenome-
non occurs during horizontal saccades in Gaucher’s dis-
ease. No abnormalities of vestibulo-ocular responses
have been found.20 Treatment is possible with
Miglustat.21
Gaucher’s disease type 2 (acute neurological form)
and type 3 (subacute neurological form) are the neuro-
nopathic forms of this lysosomal storage disorder.
Gaucher’s disease type 2 presents during infancy and
abnormalities of eye movements are early signs in
affected children, including ocular motor paralysis,
slowness of saccades, oculomotor “apraxia,” and stra-
bismus.22,23 Gaucher’s disease type 3 presents during
childhood or adolescence. Movement disorders are
common in type 3, particularly ataxia and parkinson-
ism.24 However, patients often present with (myoclo-
nus) epilepsy and supranuclear gaze palsy that only
affects horizontal gaze.25–27 Horizontal saccades are
markedly slow and may show a curved trajectory,
whereas vertical saccades are initially preserved.28–30
Vestibulo-ocular responses may be impaired.31 Ocular
motor apraxia, which in fact reﬂects abnormal patterns
of head motion associated with defects in initiation of
saccades, is also observed in Gaucher’s types 2 and
3.30,32 Similar to NP-C, patterns of abnormal saccades
can be used to monitor progression of disease.9,33
Gaucher’s disease type 1 is the chronic non-
neurological form; however, subtle slowness of sac-
cades has been reported in some patients.22,34–36
Enzyme replacement therapy and substrate reduction
therapy are available.21
In the late-onset form of Tay-Sachs disease (GM2
gangliosidosis), motor symptoms are frequent. These
are caused by motor neuron dysfunction and cerebellar
involvement with ataxia.37 Abnormalities of eye move-
ments are not a classic feature of late-onset Tays-Sachs
disease, but impaired smooth pursuit with square-wave
jerks (saccadic intrusions), transient decelerations of
saccades, and up-gaze palsy have been described.
Vestibulo-ocular responses are normal.37–40 In early-
onset Tach-Sachs disease, vertical gaze is impaired early
and horizontal gaze later in the disease.9 Treatment is
not available.
The clinical picture of Sandhoff’s disease (GM2 gang-
liosidosis) is similar to Tay-Sachs disease. Early child-
hood forms are most common. Late-onset forms of
Sandhoff’s disease are rare and have a milder phenotype.
They often present as a complex neurological disorder
with ataxia, chorea, tremor, dystonia, or parkinsonism
in combination with motor neuron dysfunction.21
Abnormalities of eye movements include impaired hori-
zontal and vertical saccades with nystagmus.41–43 A
patient with adult-onset Sandhoff’s disease and pendular
nystagmus in combination with palatal tremor has been
described.41 Treatment is not available.
Disorders of Lipid Metabolism
Signs of abetalipoproteinemia occur early in life and
progress with time. Neurological manifestations resulting
from vitamin deﬁciency often begin in the ﬁrst or second
decade of life. Low vitamin E in particular can cause
progressive neurological symptoms affecting the periph-
eral and central nervous system. Adult patients show
malabsorption, steatosis, abnormal liver transaminases,
and neurological signs.21 Abnormalities of eye move-
ments are typical, including progressive gaze distur-
bances attributed to paresis of the medial rectus muscles
and a characteristic pattern of dissociated nystagmus.
The latter consists of an intense nystagmus, but with lim-
ited range in the adducting eye, and a less-intense nystag-
mus, but with full range, in the abducting eye. Patients
complain of trouble reading and of difﬁculties associated
with impaired convergence. Saccades are slow and hypo-
metric. Vestibular nystagmus and optokinetic nystagmus
have abnormal or absent quick phases.44 A low-fat diet
with reduced long-chain fatty acids and fat-soluble vita-
min supplements is recommended.21
Late-onset cerebrotendinous xanthomatosis is charac-
terized by tendon xanthomas, psychiatric symptoms,
and neurological symptoms, including pyramidal, cere-
bellar, and extrapyramidal signs in the second or third
decade of life.21,45 Patients show abnormal pursuit,
increased saccadic intrusions, multistep saccades, and
antisaccade deﬁcits.46 Chenodeoxycolic acid and statin
therapy are an effective treatment and can prevent neu-
rological involvement if started early.21,47,48
Disorders of Carbohydrate Metabolism
Symptoms of glucose transporter type 1 deﬁciency
usually occur early in life, but may present in adoles-
cence or adulthood. In the late presentation form, par-
oxysmal exercise-induced dyskinesia occurs that
Movement Disorders, Vol. 33, No. 12, 2018 1847
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predominantly manifests as dystonia, chorea, and bal-
lism. Epilepsy is also observed.49 Abnormalities of eye
movements are common and may be highly characteris-
tic brief multidirectional paroxysmal episodes of rapid
eye movements in combination with head movements
in the same direction, a phenomenon called aberant
gaze saccades.50 Eye rolling and ﬂuttering, strabismus,
opsoclonus, and limitation of vertical eye movements
have also been described.50–52 Early diagnosis is impor-
tant because this disorder can be treated with a keto-
genic diet.21
Disorders of Mineral, Metal,
or Vitamin Metabolism
Symptoms of Wilson’s disease often begin in the teen-
age years. Liver disease is frequently the presenting sign,
but psychiatric and neurological symptoms including
movement disorders are also frequent presentations. The
Kayser-Fleischer ring, copper deposits that form a ring in
the cornea, is the ophthalmological hallmark of Wilson’s
disease.21 Abnormalities of eye movements are fre-
quently present. Impaired vertical, but sometimes also
horizontal pursuit, selective slowing of downward sac-
cades, and dysmetria of saccades are all reported.53–57
Gaze distractibility has also been described in which
patients cannot ﬁx their eyes on a stationary or moving
object for more than a few seconds without being dis-
tracted by other stimuli.58 At least 1 patient with oculo-
gyric crises has been reported on.59 Treatment is possible
with chelation therapy.21
Adult-onset hypermanganesemia with dystonia 1 is
characterized by parkinsonism, whereas children usu-
ally present with dystonia. Bilateral hyperintensities in
the basal ganglia and white matter attrobuted to accu-
mulation of manganese are typically observed on brain
imaging.21 Increased latency of saccades, misdirected
antisaccades, and multistep saccades have been
observed by one of the authors (A.R., personal observa-
tions). Chelation therapy and iron supplementation are
recommended21.
Pantothenate kinase-associated neurodegeneration
(or NBIA type 1) is the most common form of neurode-
generation with brain iron accumulation (NBIA). This is
reﬂected in the “eye-of-the-tiger” sign on brain MRI.60
Late-onset disease occurs during the second or third
decade. It is slowly progressive and is characterized by
speech problems, movement disorders, and psychiatric
symptoms.61 Horizontal and vertical supranuclear gaze
palsy, impaired saccades, abnormal optokinetic nystag-
mus, and impaired horizontal vestibulo-ocular responses
have been described.62,63 Oculogyric crisis has been
reported in 1 patient.60 Treatment with chelation ther-
apy is not effective.21
Adult-onset dystonia-parkinsonism (NBIA type 2)
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disorders causing iron accumulation. Adults usually
present before the age of 30 and have parkinsonism,
dystonia and cognitive decline. Ophthalmic features
include strabismus, up-gaze palsy, impaired pursuit
with saccadic intrusions, and pendular nystagmus.
Vestibulo-ocular responses are not impaired.64 A case
of oculogyric crisis induced by levodopa has been
described in a patient with adult-onset dystonia-parkin-
sonism.65 Only symptomatic treatment is available.
The onset of biotin-thiamine-responsive basal ganglia
disease is usually during early childhood, but can occur
later in life.21,66 In addition to acute dystonia and
encephalopathy, bilateral external ophthalmoplegia is
observed.67–69 Diagnosis is important because treat-
ment with thiamine and biotin can be life-saving.
Finally, onset of ataxia with vitamin E deﬁciency can
be at any age. Symptoms include ataxia, areﬂexia, and
impaired proprioception. Nystagmus is observed as
part of a cerebellar syndrome. Impaired smooth
pursuit, slow saccades, ocular motor apraxia, and stra-
bismus have been reported.9,70–72 Treatment is with
high-dose vitamin E supplementation.72
Disorders of Amino Acid Metabolism
Four clinical subtypes of maple syrup urine disease
(MSUD) are described. Classic MSUD presents soon
after birth and is a severe and often rapidly lethal disor-
der. The phenotypes of the other subtypes (intermedi-
ate, intermittent, and thiamine-responsive MSUD) are
overlapping. Presentation in adulthood is very rare.
Patients with MSUD may decompensate during cata-
bolic states and develop behavioral changes, nausea,
vomiting, and eventually coma attributed to cerebral
edema. Movement disorders may also be present.21
Abnormalities of eye movements are described in
infants and vary from up-gaze palsy and adduction
weakness to absence of voluntary eye movements with
absent vestibulo-ocular reﬂexes.73–75 Treatment is with
a low-protein diet in combination with a leucine-,
isoleucine-, and valine-free amino acid supplement.
Emergency treatment is necessary during metabolic
stress, such as intercurrent illnesses.21
Glutaric aciduria type 1 (GA1) usually begins in
childhood, but adult-onset has been reported as well.
Catabolic episodes and intercurrent illnesses result in
damage to the caudate nucleus and putamen, causing
severe dystonia.21 Ocular abnormalities include intrar-
etinal haemorrhages, cataract, and pigmentary retinop-
athy.76 A 19-year-old woman with GA1 showed
horizontal nystagmus, upward gaze palsy, and paralysis
of convergence.77 Other patients with gaze palsy have
been described, but gaze palsy in these patients might
be secondary to increased intracranial pressure attrib-
uted to the intracranial haemorrhages that may be pre-
sent in GA1.76 Dietary treatment with a low-lysine diet
and carnitine supplementation prevents damage to the
striatum. Similar to MSUD, emergency treatment is nec-
essary to prevent catabolism during periods of fever or
prolonged fasting.21
Congenital Disorders of Glycosylation
Phosphomannomutase 2 deﬁciency (PMM2-CDG or
CDG1A) is the most common congenital disorder of
glycosylation. The phenotype is variable, and multiple
organs can be involved.21 PMM2-CDG is usually diag-
nosed in childhood, but attenuated forms present later.
In adulthood, the symptoms may be mild and include
ataxia and learning difﬁculties.78 A whole range of ocu-
lar manifestations can occur and include strabismus,
impaired smooth pursuit, nystagmus, ocular ﬂutter,
ocular motor apraxia, impaired optokinetic nystagmus,
and impaired vestibulo-ocular reﬂexes.79–82 Strabismus
and nystagmus might be secondary to visual impair-
ment, although they are also described in patients with
PMM2-CDG who have normal vision.78,82 Other sub-
types of congenital disorders of glycosylation 1 are less
common, but some of these patients also show strabis-
mus and nystagmus.82 With the exception of a few sub-
types of CDG syndromes, treatment is not available.
Disorders of Purine or Pyrimidine Metabolism
Variants of Lesch Nyhan syndrome are described that
present in early adulthood with symptoms of hyperuri-
cemia, for example, nephrolithiasis, crystalluria, and
gout.21 Ocular motor abnormalities are observed par-
ticularly in severe (early-onset) HPRT deﬁciency and
include impaired smooth pursuit and difﬁculty initiating
voluntary saccades that appears as an ocular motor
apraxia.83 Hyperuricemia must be treated.21
Peroxisomal Disorders
In patients suffering from Zellweger spectrum disor-
ders, three different presentations can be observed: a
neonatal-infantile, a childhood, and an adolescent-adult
presentation. The majority of patients presents in child-
hood.84 The phenotype is milder when the disease
begins in adolescents or adults. Patients have mild-to-
severe cognitive impairment in combination with retinal
dystrophy, cataract, glaucoma, hearing impairment,
ataxia, pyramidal symptoms, or peripheral neuropa-
thy.21 Vision is frequently impaired.84 Ocular motor
abnormalities include hypometric saccades (particularly
in the horizontal plane), saccadic intrusions (square-
wave jerks), and gaze-evoked nystagmus.85 Pendular
nystagmus can be observed.86 No curative treatment is
available.
Neurotransmitter disorders
Disorders of neurotransmitters, especially those that
affect the dopaminergic pathways, can cause dystonia with
1852 Movement Disorders, Vol. 33, No. 12, 2018
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oculogyric crises. Response to low doses of L-dopa in some
of these diseases is excellent. Neurotransmitter disorders
can be divided into those affecting synthesis, those affecting
dopamine transport, and those affecting degradation.
Oculogyric crisis is frequently observed in disorders
affecting dopamine synthesis, whereas other abnormal-
ties of eye movements are rare in these disorders.87
Many of these disorders present early in life and, for
most of the neurotransmitter disorders, late-onset pre-
sentation is rare. Patients with milder forms of these
disorders may remain undiagnosed until adolescence or
adulthood, or may be mistakenly diagnosed with cere-
bral palsy.21 However, recognition of these disorders is
important because patients can improve dramatically
when treated properly. Most of the late-onset neuro-
transmitter disorders are caused by autosomal dominant
GTP-CH-I deﬁciency. Patients present with dystonia of
the lower limbs that usually progresses to generalized
dystonia, although the late-onset form can also be asso-
ciated with parkinsonism.88 Autosomal recessive forms
of GTP-CH-I deﬁciency have also been described. Ocu-
logyric crises are more frequent in recessive than domi-
nant forms of GTP-CH-I deﬁciency.89–91 Patients with
aromatic L-amino acid decarboxylase deﬁciency
(AADC),21,92 tyrosine hydroxylase deﬁciency,93–96 and
6-pyruvoyl-tetrahydropterin synthase deﬁciency97,98
may show oculogyric crisis, in particular in AADC in
which oculogyric crisis is one of the key features.92,99,100
Finally, oculogyric crisis is also described in sepiapterin
reductase deﬁciency.101–103
Disorders affecting dopamine transport include brain
dopamine-serotonin vesicular disease (vesicular mono-
amine transporter 2 deﬁciency) and dopamine trans-
porter deﬁciency syndrome (DAT deﬁciency). In the
latter, adult onset is reported with parkinsonism and
psychiatric symptoms.104 Both disorders are associated
with oculogyric crisis.87,105,106 Other abnormalities of
eye movements are also observed in DAT deﬁciency,
including saccadic intrusions during smooth pursuit,
saccadic oscillations (ocular ﬂutter), slow saccadic eye
movements, and ocular motor apraxia.87,104,107
Energy Metabolism Disorders
Mitochondrial diseases are a group of disorders
caused by mutations in mitochondrial DNA (mtDNA;
either maternally inherited or de novo) or nuclear DNA
(Mendelian inherited). Tissues with high energy needs
are commonly affected, including brain, heart, and skel-
etal muscles. There is a wide range of clinical pheno-
types, and onset varies widely. Neurological
involvement causes movement disorders, psychomotor
retardation or regression, epilepsy, muscle weakness,
and migraine.108 Adult onset of mitochondrial disease
is especially frequent in disorders caused by multiple
deletions in mtDNA, probably attributed to
accumulation of mtDNA defects.108 Ocular involve-
ment is frequent, and both central and peripheral
causes of eye movements can be present. A well-known
form of ocular motor dysfunction in mitochondrial dis-
ease is PEO, characterized by progressive bilateral pto-
sis and weakness of the extraocular muscles. PEO often
occurs in association with other symptoms.109 When it
is the sole feature, it is called chronic PEO. PEO is seen
in Kearn-Sayre’s syndrome, Pearson’s syndrome, and
multiple disorders attributed to mitochondrial deletions
or point mutations.110 In mitochondrial neurogastroin-
testinal encephalomyopathy, PEO is characterized by
slow and hypometric saccades, particularly for saccades
larger than 10 degrees, and abducting saccades are
slower than adducting saccades.111 Central eye move-
ment disorders are observed in patients with Leigh’s
syndrome (subacute necrotizing encephalomyelopathy).
Patients with early-onset disease show disorders similar
to those attributed to thiamine deﬁcieny, including
gaze-evoked nystagmus, impaired vestibular responses,
internuclear ophthalmoplegia, and upbeat nystagmus
switching to downbeat nystagmus during conver-
gence.9,112 A combination of PEO with central eye
movement disorders has been described in POLG-
related disorders. The phenotype of POLG-related dis-
orders is variable; it ranges from severe and often lethal
childhood forms to later-onset forms with a continuum
of overlapping phenotypes, including ophthalmople-
gia.113 In addition to ophthalmoplegia, ptosis, gaze-
evoked nystagmus, rebound nystagmus, abnormalties
of saccades (dysmetria and slowing), and impaired pur-
suit have been observed.114 Treatment of mitochondrial
diseases is still limited and includes vitamins and
cofactors.21
Pyruvate dehydrogenase deﬁciency is divided into
different subtypes. An adult patient diagnosed with
pyruvate dehydrogenase E1 deﬁciency showed parkin-
sonism, impaired up gaze, and jerky horizontal eye
movements during pursuit.115 Pendular nystagmus, eye
rolling, and ocular motor apraxia are reported in chil-
dren with pyruvate dehydrogenase E2 deﬁciency.116
The disease can be treated with a ketogenic diet, thia-
mine, L-carnitine, and α-lipoic acid.117
Conclusions
We have reviewed IEM in which the onset of symp-
toms can occur relatively late in life and in which ocu-
lar motor abnormalities can be a prominent sign.
Recognition of these patterns of abnormalities of eye
movements is important because they may be the key
to accurate early diagnosis and thus to a timely start of
treatment. Unfortunately, there continues to be a lack
of information about eye movement disorders in many
IEMs because little attention is given to them in daily
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practice. Examination of the vestibular system, in par-
ticular, is neglected in most studies even though it often
provides essential information about localization and
diagnosis. Disorders of hearing are commonly recog-
nized in many IEMs, but vestibular function is rarely
commented upon. A standard, focused examination of
the different subtypes of eye movements (range of
motion, gaze-holding, saccades, pursuit, and vestibular
responses) can be performed relatively quickly in most
patients during routine physical examination. Testing
with video-oculography has also become more user-
and patient-friendly and helps to quantify the eye
movement abnormalities, making these abnormalities a
valuable biomarker for following the natural course of
disease or the response to therapies.
Acknowledgments: The authors thank Kate McIntyre, editor of the
Department of Genetics, for editing the manuscript.
References
1. Ahrens-Nicklas RC, Slap G, Ficicioglu C. Adolescent presentations
of inborn errors of metabolism. Journal of Adolescent Health
2015;56:477-482.
2. Sanderson SS. The incidence of inherited metabolic disorders in the
West Midlands, UK. Arch Dis Child 2006;91:896-899.
3. Walter John J. IEMs in adults. J Inherit Metab Dis 2007;30:627.
4. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat
for treatment of Niemann-Pick C disease: a randomised controlled
study. Lancet Neurol 2007;6:765-772.
5. Sedel F, Saudubray JM, Roze E, Agid Y, Vidailhet M. Movement
disorders and inborn errors of metabolism in adults: a diagnostic
approach. J Inherit Metab Dis 2008;31:308-318.
6. Poll-The BT, Maillette de Buy Wenniger-Prick, C J. The eye in met-
abolic diseases: clues to diagnosis. Eur J Paediatr Neurol 2011;15:
197-204.
7. Strupp M, Hüfner K, Sandmann R, Zwergal A, Dieterich M,
Jahn K, Brandt T. Central oculomotor disturbances and nystagmus:
a window into the brainstem and cerebellum. Dtsch Arztebl Int
2011;108:197-204.
8. Petty RK, Harding AE, Morgan-Hughes JA. The clinical features of
mitochondrial myopathy. Brain 1986;109:915-938.
9. Leigh RJ, Zee DS. The Neurology of Eye Movements, 5th ed. -
New York, NY: Oxford University Press; 2015.
10. Strupp M, Kremmyda O, Adamczyk C, Bottcher N, Muth C,
Yip CW, Bremova T. Central ocular motor disorders, including
gaze palsy and nystagmus. J Neurol 2014;261(Suppl 2):S542-S545.
11. McCaslin DL. Electronystagmography/Videonystagmography. San
Diego, CA: Plural; 2013.
12. Gans RE. Video-oculography: a new diagnostic technology for ves-
tibular patients. Hearing J 2001;54:40-42.
13. Abel LA, Walterfang M, Stainer MJ, Bowman EA, Velakoulis D.
Longitudinal assessment of reﬂexive and volitional saccades in
Niemann-Pick Type C disease during treatment with miglustat.
Orphanet J Rare Dis 2015;10:160.
14. Koens LH, Kuiper A, Coenen MA, et al. Ataxia, dystonia and
myoclonus in adult patients with Niemann-Pick type C. Orphanet J
Rare Dis 2016;11:121.
15. Wijburg FA, Sedel F, Pineda M et al. Development of a suspicion
index to aid diagnosis of Niemann-Pick disease type C. Neurology
2012;78:1560-1567.
16. Rottach KG, von Maydell RD, Das VE et al. Evidence for indepen-
dent feedback control of horizontal and vertical saccades from
Niemann-Pick type C disease. Vision Res 1997;37:3627-3638.
17. Neville BG, Lake BD, Stephens R, Sanders MD. A neurovisceral
storage disease with vertical supranuclear ophthalmoplegia, and its
relationship to Niemann-Pick disease. A report of nine patients.
Brain 1973;96:97-120.
18. Abel LA, Walterfang M, Fietz M, Bowman EA, Velakoulis D.
Saccades in adult Niemann-Pick disease type C reﬂect frontal,
brainstem, and biochemical deﬁcits. Neurology 2009;72:
1083-1086.
19. Eggink Hendriekje H. Teaching Video NeuroImages: The “round
the houses” sign as a clinical clue for Niemann-Pick disease type C.
Neurology 2016;86:e202.
20. Bremova T, Krafczyk S, Bardins S, Reinke J, Strupp M. Vestibular
function in patients with Niemann-Pick type C disease. J Neurol
2016;263:2260-2270.
21. Hollak CEM, Lachman R. Inherited Metabolic Disease in
Adults: A Clinical Guide. New York, NY: Oxford University
Press; 2016.
22. Accardo AP, Pensiero S, Perissutti P. Saccadic analysis for early
identiﬁcation of neurological involvement in Gaucher disease. Ann
N Y Acad Sci 2005;1039:503-507.
23. Mignot C, Doummar D, Maire I, De Villemeur TB. Type 2 Gaucher
disease: 15 new cases and review of the literature. Brain Dev 2006;28:
39-48.
24. Tylki-Szymanska A, Vellodi A, El-Beshlawy A, Cole JA,
Kolodny E. Neuronopathic Gaucher disease: demographic and clin-
ical features of 131 patients enrolled in the International Collabo-
rative Gaucher Group Neurological Outcomes Subregistry. J
Inherit Metab Dis 2010;33:339-346.
25. Cogan DG, Chu FC, Reingold D, Barranger J. Ocular motor signs
in some metabolic diseases. Arch Ophthalmol 1981;99:1802-1808.
26. Accardo A, Pensiero S, Ciana G, Parentin F, Bembi B. Eye move-
ment impairment recovery in a Gaucher patient treated with miglu-
stat. Neurol Res Int 2010;2010:358534.
27. Park JK, Orvisky E, Tayebi N et al. Myoclonic epilepsy in Gaucher
disease: genotype-phenotype insights from a rare patient subgroup.
Pediatr Res 2003;53:387-395.
28. Sharma S, Lal V, Das R. Horizontal gaze palsy with progressive
myoclonic epilepsy: rare presentation of Gaucher’s disease. Neurol
India 2013;61:177-178.
29. Benko W, Ries M, Wiggs EA, Brady RO, Schiffmann R,
Fitzgibbon EJ. The saccadic and neurological deﬁcits in type
3 Gaucher disease. PLoS One 2011;6:e22410.
30. Accardo A, Bembi B, Pensiero S, Perissutti P. Type 3 Gaucher’s dis-
ease in a three-year-old child: saccadic eye movements analysis. J
AAPOS 2005;9:501-503.
31. Chen L, Halmagyi GM, Todd MJ, Aw ST. Vestibular and
Saccadic Abnormalities in Gaucher’s Disease. JIMD Rep 2014;13:
111-118.
32. Gross-Tsur V, Har-Even Y, Gutman I, Amir N. Oculomotor
apraxia: the presenting sign of Gaucher disease. Pediatr Neurol
1989;5:128-129.
33. Blume J, Beniaminov S, Kämpe Björkvall C, Machaczka M,
Svenningsson P. Saccadic impairments in patients with the norrbott-
nian form of Gaucher’s disease type 3. Front Neurol 2017;8:295.
34. Pastores GM, Barnett NL, Bathan P, Kolodny EH. A neurological
symptom survey of patients with type I Gaucher disease. J Inherit
Metab Dis 2003;26:641-645.
35. Capablo JL, Saenz de Cabezon A, Fraile J, Alfonso P, Pocovi M,
Giraldo P, Spanish Group on Gaucher Disease. Neurological evalu-
ation of patients with Gaucher disease diagnosed as type 1. J Neu-
rol Neurosurg Psychiatry 2008;79:219-222.
36. Sidransky E, Tsuji S, Stubbleﬁeld BK, Currie J, FitzGibbon EJ,
Ginns EI. Gaucher patients with oculomotor abnormalities do not
have a unique genotype. Clin Genet 1992;41:1-5.
37. Rucker JC, Shapiro BE, Han YH, Kumar AN, Garbutt S,
Keller EL, Leigh RJ. Neuro-ophthalmology of late-onset Tay-Sachs
disease (LOTS). Neurology 2004;63:1918-1926.
1854 Movement Disorders, Vol. 33, No. 12, 2018
K O E N S E T A L .
38. Optican LM, Rucker JC, Keller EL, Leigh RJ. Mechanism of inter-
rupted saccades in patients with late-onset Tay-Sachs disease. Prog
Brain Res 2008;171:567-570.
39. Barnes D, Misra VP, Young EP, Thomas PK, Harding AE. An
adult onset hexosaminidase A deﬁciency syndrome with sensory
neuropathy and internuclear ophthalmoplegia. J Neurol Neurosurg
Psychiatry 1991;54:1112-1113.
40. Hund E, Grau A, Fogel W et al. Progressive cerebellar ataxia, prox-
imal neurogenic weakness and ocular motor disturbances: hexosa-
minidase A deﬁciency with late clinical onset in four siblings. J
Neurol Sci 1997;145:25-31.
41. Pretegiani E, Rosini F, Federighi P, Cerase A, Dotti MT, Rufa A.
Pendular nystagmus, palatal tremor and progressive ataxia in
GM2-gangliosidosis. Eur J Neurol 2015;22:e67-e69.
42. Masri A, Liao J, Kornreich R, Haghighi A. Homozygous p.R284*
mutation in HEXB gene causing Sandhoff disease with nystagmus.
Eur J Paediatr Neurol 2014;18:399-403.
43. Yun YM, Lee SN. A case refort of Sandhoff disease. Korean J
Ophthalmol 2005;19:68-72.
44. Yee RD, Cogan DG, Zee DS. Ophthalmoplegia and dissociated
nystagmus in adetalipoproteinemia. Arch Ophthalmol 1976;94:
571-575.
45. Federico A, Dotti MT, Gallus GN. Cerebrotendinous Xanthomato-
sis. In: Pagon RA, Adam MP, Ardinger HH et al. GeneReviews(®).
Seattle (WA): University of Washington, Seattle 1993-2017.
46. Rosini F, Pretegiani E, Mignarri A et al. The role of dentate nuclei
in human oculomotor control: insights from cerebrotendinous
xanthomatosis. J Physiol (Lond ) 2017;595:3607-3620.
47. Berginer VM, Gross B, Morad K, Kﬁr N, Morkos S, Aaref S,
Falik-Zaccai TC. Chronic diarrhea and juvenile cataracts: think
cerebrotendinous xanthomatosis and treat. Pediatrics 2009;123:
143-147.
48. Van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO,
Tolboom JJ. Treatment and follow-up of children with cerebroten-
dinous xanthomatosis. Eur J Pediatr 1998;157:313-316.
49. De Giorgis V, Varesio C, Baldassari C et al. Atypical manifesta-
tions in Glut1 deﬁciency syndrome. J Child Neurol 2016;31:
1174-1180.
50. Pearson TS, Pons R, Engelstad K, Kane SA, Goldberg ME, De
Vivo DC. Paroxysmal eye-head movements in Glut1 deﬁciency syn-
drome. Neurology 2017; 88:1666-1673.
51. Akman CI, Yu J, Alter A, Engelstad K, De Vivo DC. Diagnosing
glucose transporter 1 deﬁciency at initial presentation facilitates
early treatment. J Pediatr 2016;171:220-226.
52. Ito Y, Takahashi S, Kagitani-Shimono K, Natsume J,
Yanagihara K, Fujii T, Oguni H. Nationwide survey of glucose
transporter-1 deﬁciency syndrome (GLUT-1DS) in Japan. Brain
Dev 2015;37:780-789.
53. Hyman NM, Phuapradit P. Reading difﬁculty as a presenting
symptom in Wilson’s disease. J Neurol Neurosurg Psychiatry 1979;
42:478-480.
54. Jung H, Choi SY, Kim J, Kim J. Selective slowing of downward
saccades in Wilson's disease. Parkinsonism Relat Disord 2013;19:
134-135.
55. Ingster-Moati I, Bui Quoc E, Pless M, Djomby R, Orssaud C,
Guichard JP, Woimant F. Ocular motility andWilson’s disease: a study
on 34 patients. J Neurol Neurosurg Psychiatry 2007;78:1199-1201.
56. Lesniak M, Czlonkowska A, Seniow J. Abnormal antisaccades and
smooth pursuit eye movements in patients with Wilson’s disease.
Mov Disord 2008;23:2067-2073.
57. Kirkham TH, Kamin DF. Slow saccadic eye movements in Wilson’s
disease. J Neurol Neurosurg Psychiatry 1974;37:191-194.
58. Lennox G, Jones R. Gaze distractibility in Wilson’s disease. Ann
Neurol 1989;25:415-417.
59. Lee MS, Kim YD, Lyoo CH. Oculogyric crisis as an initial manifes-
tation of Wilson’s disease. Neurology 1999;52:1714-1715.
60. Zupanc ML, Chun RW, Gilbert-Barness EF. Osmiophilic deposits
in cytosomes in Hallervorden-Spatz syndrome. Pediatr Neurol
1990;6:349-352.
61. Hayﬂick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA,
Ching KHL, Gitschier J. Genetic, clinical, and radiographic delinea-
tion of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:
33-40.
62. Egan RA, Weleber RG, Hogarth P et al. Neuro-ophthalmologic
and electroretinographic ﬁndings in pantothenate kinase-associated
neurodegeneration (formerly Hallervorden-Spatz syndrome).
Am J Ophthalmol 2005;140:267-274.
63. Bozi M, Matarin M, Theocharis I, Potagas C, Stefanis L. A patient
with pantothenate kinase-associated neurodegeneration and supra-
nuclear gaze palsy. Clin Neurol Neurosurg 2009;111:688-690.
64. Khan AO, AlDrees A, Elmalik SA et al. Ophthalmic features of
PLA2G6-related paediatric neurodegeneration with brain iron
accumulation. Br J Ophthalmol 2014;98:889-893.
65. Virmani T, Thenganatt MA, Goldman JS, Kubisch C, Greene PE,
Alcalay RN. Oculogyric crises induced by levodopa in PLA2G6
parkinsonism-dystonia. Parkinsonism Relat Disord 2014;20:
245-247.
66. Alfadhel M, Almuntashri M, Jadah RH et al. Biotin-responsive
basal ganglia disease should be renamed biotin-thiamine-responsive
basal ganglia disease: a retrospective review of the clinical, radio-
logical and molecular ﬁndings of 18 new cases. Orphanet J Rare
Dis 2013;8:83.
67. Fassone E, Wedatilake Y, DeVile CJ, Chong WK, Carr LJ,
Rahman S. Treatable Leigh-like encephalopathy presenting in ado-
lescence. BMJ Case Rep 2013;2013:200838.
68. Tabarki B, Al-Sheikh F, Al-Shahwan S, Zuccoli G. Bilateral exter-
nal ophthalmoplegia in biotin-responsive basal ganglia disease. J
Pediatr 2013;162:1291-1292.
69. Ozand PT, Gascon GG, Al Essa M, et al. Biotin-responsive basal
ganglia disease: a novel entity. Brain 1998;121:1267-1279.
70. El Euch-Fayache G, Bouhlal Y, Amouri R, Feki M, Hentati F.
Molecular, clinical and peripheral neuropathy study of Tunisian
patients with ataxia with vitamin E deﬁciency. Brain 2014;137:
402-410.
71. Tamaru Y, Hirano M, Kusaka H, Ito H, Imai T, Ueno S.
alpha-Tocopherol transfer protein gene: exon skipping of all tran-
scripts causes ataxia. Neurology 1997;49:584-588.
72. Gabsi S, Gouider-Khouja N, Belal S, et al. Effect of vitamin E sup-
plementation in patients with ataxia with vitamin E deﬁciency. Eur
J Neurol 2001;8:477-481.
73. Zee DS, Freeman JM, Holtzman NA. Ophthalmoplegia in maple
syrup urine disease. J Pediatr 1974;84:113-115.
74. Gupta B, Waggoner D. Ophthalmoplegia in maple syrup urine dis-
ease. J AAPOS 2003;7:300-302.
75. Chhabria S, Tomasi LG, Wong PW. Ophthalmoplegia and bulbar
palsy in variant form of maple syrup urine disease. Ann Neurol
1979;6:71-72.
76. Kaﬁl-Hussain NA, Monavari A, Bowell R, Thornton P,
Naughten E, O’Keefe M. Ocular ﬁndings in glutaric aciduria type
1. J Pediatr Ophthalmol Strabismus 2000;37:289-293.
77. Bahr O, Mader I, Zschocke J, Dichgans J, Schulz JB. Adult onset
glutaric aciduria type I presenting with a leukoencephalopathy.
Neurology 2002;59:1802-1804.
78. Vermeer S, Kremer HPH, Leijten QH, et al. Cerebellar ataxia and
congenital disorder of glycosylation Ia (CDG-Ia) with normal rou-
tine CDG screening. J Neurol 2007;254:1356-1358.
79. Messenger WB, Yang P, Pennesi ME. Ophthalmic ﬁndings in an
infant with phosphomannomutase deﬁciency. Doc Ophthalmol
2014;128:149-153.
80. Coorg R, Lotze TE. Child Neurology: a case of PMM2-CDG
(CDG 1a) presenting with unusual eye movements. Neurology
2012;79:e131-e133.
81. Stark KL, Gibson JB, Hertle RW, Brodsky MC. Ocular motor signs
in an infant with carbohydrate-deﬁcient glycoprotein syndrome
type Ia. Am J Ophthalmol 2000;130:533-535.
82. Morava E, Wosik HN, Sykut-Cegielska J, et al. Ophthalmological
abnormalities in children with congenital disorders of glycosylation
type I. Br J Ophthalmol 2009;93:350-354.
Movement Disorders, Vol. 33, No. 12, 2018 1855
E Y E M O V E M E N T D I S O R D E R S I N L A T E - O N S E T I E M
83. Jinnah HA, Lewis RF, Visser JE, Eddey GE, Barabas G, Harris JC.
Ocular motor dysfunction in Lesch-Nyhan disease. Pediatr Neurol
2001;24:200-204.
84. Poll-The BT, Gootjes J, Duran M, et al. Peroxisome biogenesis dis-
orders with prolonged survival: phenotypic expression in a cohort
of 31 patients. Am J Med Genet A 2004;126A:333-338.
85. Rosini F, Vinciguerra C, Mignarri A, Di Giovanni M, Federico A,
Rufa A. Eye movement abnormalities in a patient with Zellweger
spectrum disorder. Neurol Sci 2016;37:1013-1015.
86. Kori AA, Robin NH, Jacobs JB, et al. Pendular nystagmus in
patients with peroxisomal assembly disorder. Arch Neurol 1998;
55:554-558.
87. Kurian MA, Li Y, Zhen J, et al. Clinical and molecular characteri-
sation of hereditary dopamine transporter deﬁciency syndrome: an
observational cohort and experimental study. Lancet Neurol 2011;
10:54-62.
88. Wijemanne S, Jankovic J. Dopa-responsive dystonia-clinical and
genetic heterogeneity. Nat Rev Neurol 2015;11:414-424.
89. Horvath GA, Stockler-Ipsiroglu SG, Salvarinova-Zivkovic R,
et al. Autosomal recessive GTP cyclohydrolase I deﬁciency without
hyperphenylalaninemia: evidence of a phenotypic continuum
between dominant and recessive forms. Mol Genet Metab 2008;
94:127-131.
90. Furukawa Y, Kish SJ, Bebin EM, et al. Dystonia with motor delay
in compound heterozygotes for GTP-cyclohydrolase I gene muta-
tions. Ann Neurol 1998;44:10-16.
91. Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guano-
sine triphosphate cyclohydrolase I deﬁciency (Segawa disease). Ann
Neurol 2003;54(Suppl 6):S32-S45.
92. Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guide-
line for the diagnosis and treatment of aromatic l-amino acid
decarboxylase (AADC) deﬁciency. Orphanet J Rare Dis 2017;
12:12.
93. Al-Muslamani AM, Ali F, Mahmood F. A new tyrosine hydroxy-
lase genotype with orofacial dyskinaesia. Sultan Qaboos Univ Med
J 2014;14:397-400.
94. Furukawa Y, Kish S. Tyrosine hydroxylase deﬁciency. In:
Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews(R).
Seattle, WA: University of Washington, Seattle; 1993-2017.
95. Grattan-Smith PJ, Wevers RA, Steenbergen-Spanjers GC, Fung VS,
Earl J, Wilcken B. Tyrosine hydroxylase deﬁciency: clinical mani-
festations of catecholamine insufﬁciency in infancy. Mov Disord
2002;17:354-359.
96. Zafeiriou DI, Ververi A, Salomons GS, et al. L-2-Hydroxyglutaric
aciduria presenting with severe autistic features. Brain Dev 2008;
30:305-307.
97. Leuzzi V, Carducci CA, Carducci CL, et al. Phenotypic variability, neuro-
logical outcome and genetics background of 6-pyruvoyl-tetrahydropterin
synthase deﬁciency. ClinGenet 2010;77:249-257.
98. Jäggi L, Zurﬂüh MR, Schuler A, et al. Outcome and long-term
follow-up of 36 patients with tetrahydrobiopterin deﬁciency. Mol
Genet Metab 2008;93:295-305.
99. Kojima K, Anzai R, Ohba C, et al. A female case of aromatic
l-amino acid decarboxylase deﬁciency responsive to MAO-B inhibi-
tion. Brain Dev 2016;38:959-963.
100. Lee WT, Lin JH, Weng WC, Peng SS. Microstructural changes of
brain in patients with aromatic L-amino acid decarboxylase deﬁ-
ciency. Hum Brain Mapp 2016; 38:1532-1540.
101. Friedman J, Roze E, Abdenur JE, et al. Sepiapterin reductase deﬁciency:
a treatable mimic of cerebral palsy. Ann Neurol 2012;71:520-530.
102. Neville BG, Parascandalo R, Farrugia R, Felice A. Sepiapterin
reductase deﬁciency: a congenital dopa-responsive motor and cog-
nitive disorder. Brain 2005;128:2291-2296.
103. Koht J, Rengmark A, Opladen T, et al. Clinical and genetic studies
in a family with a novel mutation in the sepiapterin reductase gene.
Acta Neurol Scand Suppl 2014;(198):7-12.
104. Hansen FH, Skjørringe T, Yasmeen S, et al. Missense dopamine
transporter mutations associate with adult parkinsonism and
ADHD. J Clin Invest 2014;124:3107-3120.
105. Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin
vesicular transport disease and its treatment. N Engl J Med 2013;
368:543-550.
106. Jacobsen JC, Wilson C, Cunningham V, et al. Brain dopamine-
serotonin vesicular transport disease presenting as a severe infantile
hypotonic parkinsonian disorder. J Inherit Metab Dis 2016;39:
305-308.
107. Ng J, Zhen J, Meyer E, et al. Dopamine transporter deﬁciency syn-
drome: phenotypic spectrum from infancy to adulthood. Brain
2014;137:1107-1119.
108. DiMauro S, Garone C. Metabolic disorders of fetal life:
Glycogenoses and mitochondrial defects of the mitochondrial respi-
ratory chain. Semin Fetal Neonatal Med 2011;16:181-189.
109. McClelland C, Manousakis G, Lee MS. Progressive external
ophthalmoplegia. Curr Neurol Neurosci Rep 2016;16:53.
110. Zhu CC, Traboulsi EI, Parikh S. Ophthalmological ﬁndings in 74
patients with mitochondrial disease. Ophthalmic Genet 2016:38:67-69.
111. Vinciguerra C, Federighi P, Rosini F, et al. Eye movement changes
in mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE). J Neurol Sci 2015;350:107-109.
112. Han J, Lee YM, Kim SM, Han SY, Lee JB, Han SH. Ophthalmo-
logical manifestations in patients with Leigh syndrome. Br J
Ophthalmol 2015;99:528-535.
113. Cohen BH, Chinnery PF, Copeland WC. POLG-related disorders.
In: Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews(®).
Seattle, WA: University of Washington, Seattle; 1993-2017.
114. Finsterer J, Zarrouk-Mahjoub S, Daruich A. The eye on mitochon-
drial disorders. J Child Neurol 2016;31:652-662.
115. Mellick G, Price L, Boyle R. Late-onset presentation of pyruvate
dehydrogenase deﬁciency. Mov Disord 2004;19:727-729.
116. Head RA, Brown RM, Zolkipli Z, Shahdadpuri R, King MD,
Clayton PT, Brown GK. Clinical and genetic spectrum of pyruvate
dehydrogenase deﬁciency: dihydrolipoamide acetyltransferase
(E2) deﬁciency. Ann Neurol 2005;58:234-241.
117. Sofou K, Dahlin M, Hallböök T, Lindefeldt M, Viggedal G,
Darin N. Ketogenic diet in pyruvate dehydrogenase complex deﬁ-
ciency: short- and long-term outcomes. J Inherit Metab Dis 2017;
40:237-245.
Supporting Data
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site.
1856 Movement Disorders, Vol. 33, No. 12, 2018
K O E N S E T A L .
